CK Clinical

GlaxoSmithKline has come top of a new analysis which rates 20 drugmakers and their ability to get their products to the world’s poorest people.The Access to Medicines Foundation in Haarlem, the Netherlands says that the world’s largest pharmaceutical companies “differ strongly in their efforts to provide millions of people in low-income countries with better access to affordable drugs and vaccines”. Some are making solid strides, for example by developing new medicines against previously neglected diseases, but others are lagging behind in adapting similar policies.

The foundation has published its Access to Medicine Index and says that “rather than looking at the pharmaceutical industry as a black box”, it finds “good practices within individual companies and holds them up as shining examples to others,” said Wim Leereveld, the index’ founder. He adds that the analysis will also give governments, researchers and non-governmental organisations “that work to increase poor people’s access to healthcare the opportunity to find suitable industry partners”.

The first list puts GlaxoSmithKline at the top, followed by Novo Nordisk, Merck & Co, Novartis and Sanofi-Aventis. Bringing up the rear is Schering-Plough and the next four bottom-rated firms are (from 19th to 16th) are Teva, Wyeth, Pfizer and Ranbaxy.

The position of Novartis (4th) and Abbott Laboratories (12th) has raised eyebrows in certain quarters. The Swiss major was involved in a bitter case after India’s patent office’s decision to decline coverage for a new version of the leukaemia drug Glivec/Gleevec (imatinib) and Novartis’ decision to challenge the judgment led to criticism from a number of charities and other NGOs. Last March, Abbott said it will not market any new drugs in Thailand following the government’s decision to issue a compulsory license for the company’s HIV drug Kaletra (lopinavir/ritonavir).

The Access to Medicine Index rates “dozens of indicators grouped into eight main criteria”. These include companies’ management of policies increasing access, the amount of R&D in the ‘neglected diseases’ area, patenting and licensing policies and the use of fair pricing systems. “For global pharma companies, managing access to medicine is a complex and daunting challenge,” said Matthew Kiernan, chief executive of Innovest Strategic Value Advisors, which carried out the research.

He concluded by saying that “we view companies who do it best as better managed and more far-sighted overall, and therefore more attractive to strategic, long-term investors”.

Original story can be found at: http://www.pharmatimes.com/WorldNews/article.aspx?id=13703

Working as Medical Writing Manager in a leading Pharmaceutical company, you will be required to ensure that all medical writing documents are prepared for Drug Development programmes within the company. These documents need to be prepared according to rigorous, objective and informative medical writing procedures and processes.

You will lead the Medical Writing activities for the US, European or other regulatory submissions as assigned. You will need to ensure that documents for clinical trials are prepared, reviewed, and approved in a timely and accurate manner such that the data presented will withstand examination by regulatory bodies. (more…)

Location: Cambridge, Ref: 15505

We are recruiting for a Medical Writer to join a friendly Medical Communications team.Your main role will be to write, edit and design a wide range of medical communications materials including marketing promotional and training materials. (more…)

On February 7th CK Clinical opened the new office in Chesterfield. The purpose built premises has been the home of the team for nearly 4 months now but now they are settled in, the time was right for the official opening. The launch was attended by representitives from suppliers, clients and proffessional bodies.

Jonathan Hart-Smith Manaing Director said:

“We are proud of our team including the accounts and finance team based here in Chesterfield. They do a fantastic job of making sure that the finance runs smoothly and most importantly that our contract and temporary workforce get paid on time. Its one of our key selling points that the contract staff we work with in Clinical Operations, Drug safety and Data Management are treated with respect and proffessional courtesy so its important to us that the team supporting them have a good working environment.”

The Derbyshire office also enables CK Clinical to be closer to many of clients in the North of England.

CK Clinical are proud to announce that following continued growth and success in the recruitment of Pharmacovigilance and Medical Information proffessionals, this team has continued to grow. Hendre Moolman is to join the team bringing with him strong Business Development and Consultancy skills in order to help drive forward further growth in this sector.

CK Clinical have launched a new area to their websites including articles and news stories related to the company

CK Clinical recently ran an advertising campaign to attract the best talent in Pharmacovigilance and Drug Safety for Ipsen in Slough. This role has been made available due to expansion of the team and CK Clinical are still actively recruiting for the right person. (more…)